February 20, 2025
For patients with previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC), the combination of enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) (EV+P) continued to provide significant […]
February 19, 2025
Genetic testing should be offered to myeloma patients to identify high-risk cases earlier and enable more targeted and effective treatment, according to experts. A study by […]
February 19, 2025
TOPLINE: Patients with cerebral venous thrombosis (CVT) had a threefold higher risk for cancer than individuals in the general population, according to a new study. Men […]
February 19, 2025
SAN FRANCISCO — A gene signature panel could help identify men with localized prostate cancer who would benefit from radiotherapy dose escalation in both the definitive […]
February 19, 2025
TOPLINE: The new Sassun-Mayo staging system, which integrates tumor deposit and lymph node counts, improves prognostic accuracy for patients with colon cancer compared to the standard […]
February 18, 2025
TOPLINE: Pembrolizumab provided clinical benefit in previously treated advanced clear cell gynaecological cancer (CCGC). METHODOLOGY: A single-arm multicentre phase 2 trial conducted at five UK centres […]
February 18, 2025
Pancreatic cancer remains one of the most challenging cancers to diagnose early, with almost half of patients presenting with metastatic disease. Now, a growing body of […]
February 17, 2025
TOPLINE: Patients who experienced acute genitourinary and gastrointestinal toxicities following prostate cancer radiotherapy (RT) were more likely to have late toxicities and to experience declines in […]
February 14, 2025
The US Food and Drug Administration has approved vimseltinib (Romvimza, Deciphera Pharmaceuticals, LLC) to treat adult patients with symptomatic tenosynovial giant cell tumors (TGCT) who will […]